Vogt Frederick G reported tax withholding involving 191,303 shares of IOVANCE BIOTHERAPEUTICS, INC. at $8.09 for −$1.55M on Nov 11, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
Interim CEO & General Counsel
Interim CEO & General Counsel
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,547,641.27Shares × reported price
Shares traded
191,303Common Stock
Price per share
$8.09Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
604,144Direct
Trade date
Nov 11, 2026Tax withholding
Filed
Nov 13, 2026, 5:00 PM ET2-day reporting delay
Accession
0001104659-26-127199Code F · Transaction 400999
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Option exercise200,000$7.55$1,510,000Trade 400998
Nov 11, 2026Option exercise200,000$0.00$0Trade 401000
3 transaction rows in this filing. Joint filers share the same rows.

IOVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IOVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +88%1w ago +9.3%1d ago +9.3%
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents shares acquired upon the exercise of a stock option granted on November 14, 2016 covering 200,000 shares of the Issuer's common stock at an exercise price of $7.55 per share. The option was scheduled to expire on November 14, 2026. The Reporting Person exercised the option because of its impending expiration, during an open trading window, and did not receive any cash proceeds from the exercise. The net result of the exercise was an increase of 8,697 shares in the Reporting Person's holdings of the Issuer's common stock. F2: Represents shares withheld by the Issuer in a net exercise of the option, consisting of 186,651 shares withheld to pay the exercise price of the option and 4,652 shares withheld to satisfy the mandatory tax withholding requirements upon exercise of the option, in each case valued at the closing price of the Issuer's common stock on the transaction date. No shares were sold in the open market. This is not an open market sale of securities. F3: Represents common stock remaining after deducting the common stock withheld for the exercise price and taxes. F4: The option was fully vested and exercisable as of the transaction date.